GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline today and set a price target of £13.97. The company’s shares opened today at p1,424.50. Take advantage of TipRanks Premium ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on GlaxoSmithKline. The company’s shares closed yesterday at $37.67. Take advantage of TipRanks Premium at 50% off!

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

Hengrui Pharma partners with GSK to develop 12 innovative medicines, boosting globalization for Hengrui and expanding GSK's oncology and RI&I pipeline.

LONDON (AP) — LONDON (AP) — GSK plc (GSK) on Wednesday reported second-quarter earnings of $1.93 billion. The London-based company said it had profit of 94 cents per share. Earnings, adjusted for ...

Glaxosmithkline Share Chat. Chat About GSK Shares - Stock Quote, Charts, Trade History, Share Chat, Financial Terms Glossary.

GSK plc (NYSE:GSK) is one of the best cheap stocks under $50 to buy now. On July 15, BofA analyst Sachin Jain maintained a Sell rating on GSK plc (NYSE:GSK) and set a price target of p1,510.00 ...